AAA
ADCT icon

Affinity Asset Advisors’s ADC Therapeutics ADCT Stock Holding History

Affinity Asset Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-474,744
Closed -$1.5M – 87
2024
Q2 		$1.5M Buy
+474,744
New +$1.89M 0.24% 73
2024
Q1 		– Sell
-1,013,540
Closed -$1.68M – 96
2023
Q4 		$1.68M Sell
1,013,540
-86,460
-8% -$79.8K 0.34% 58
2023
Q3 		$987K Buy
1,100,000
+500,000
+83% +$665K 0.32% 60
2023
Q2 		$1.29M Hold
600,000
– – 0.51% 43
2023
Q1 		$1.17M Buy
+600,000
New +$2.21M 0.45% 53

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $849M AUM 470.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return